Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
NCT00496795
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Stage III Breast Cancer AJCC V7
Interventions
OTHER:
epirubicin/docetaxel sequential
Sponsor
University of Bergen
Collaborators
[object Object]